Compugen Appoints Michele Holcomb, Ph.D., to Board with 30-Year Biotech Leadership
Compugen has appointed Michele Holcomb, Ph.D., as an independent director effective February 11, 2026. Dr. Holcomb brings over 30 years of biotech and healthcare experience including senior roles at Cardinal Health, Teva Pharmaceuticals and McKinsey & Company.
1. Appointment Details
Compugen appointed Michele Holcomb, Ph.D., as an independent director on February 11, 2026, expanding its board with seasoned leadership.
2. Professional Background
Holcomb brings over three decades of experience across biotech, pharmaceuticals and healthcare services, including roles as EVP and Chief Strategy Officer at Cardinal Health, COO of Global R&D at Teva Pharmaceuticals, and partner in McKinsey & Company's Global Pharmaceutical Practice.
3. Strategic Implications
Holcomb’s expertise is expected to support board governance and value creation as Compugen advances its AI/ML-powered discovery platform and clinical pipeline, notably its Phase 1 anti-TIGIT antibody COM902 and Phase 3 PD-1/TIGIT bispecific rilvegostomig with AstraZeneca.